Genmab A/S (GMAB)
27.72
-1.00
(-3.48%)
USD |
NASDAQ |
May 02, 16:00
27.72
0.00 (0.00%)
After-Hours: 16:58
Genmab Price to Book Value: 3.854 for May 2, 2024
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| May 01, 2024 | 3.993 |
| April 30, 2024 | 3.849 |
| April 29, 2024 | 3.972 |
| April 26, 2024 | 3.913 |
| April 25, 2024 | 3.817 |
| April 24, 2024 | 3.958 |
| April 23, 2024 | 3.970 |
| April 22, 2024 | 4.027 |
| April 19, 2024 | 3.990 |
| April 18, 2024 | 3.938 |
| April 17, 2024 | 3.966 |
| April 16, 2024 | 4.091 |
| April 15, 2024 | 4.102 |
| April 12, 2024 | 4.068 |
| April 11, 2024 | 4.134 |
| April 10, 2024 | 4.164 |
| April 09, 2024 | 4.166 |
| April 08, 2024 | 4.151 |
| April 05, 2024 | 4.137 |
| April 04, 2024 | 4.122 |
| April 03, 2024 | 4.073 |
| April 02, 2024 | 4.165 |
| April 01, 2024 | 4.208 |
| March 28, 2024 | 4.158 |
| March 27, 2024 | 4.258 |
| Date | Value |
|---|---|
| March 26, 2024 | 4.286 |
| March 25, 2024 | 4.168 |
| March 22, 2024 | 4.159 |
| March 21, 2024 | 4.109 |
| March 20, 2024 | 4.093 |
| March 19, 2024 | 4.120 |
| March 18, 2024 | 4.128 |
| March 15, 2024 | 4.162 |
| March 14, 2024 | 4.212 |
| March 13, 2024 | 4.357 |
| March 12, 2024 | 4.369 |
| March 11, 2024 | 4.404 |
| March 08, 2024 | 4.212 |
| March 07, 2024 | 4.088 |
| March 06, 2024 | 4.012 |
| March 05, 2024 | 3.997 |
| March 04, 2024 | 3.963 |
| March 01, 2024 | 4.072 |
| February 29, 2024 | 3.864 |
| February 28, 2024 | 3.850 |
| February 27, 2024 | 4.042 |
| February 26, 2024 | 4.088 |
| February 23, 2024 | 4.054 |
| February 22, 2024 | 4.051 |
| February 21, 2024 | 4.029 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
3.679
Minimum
Feb 13 2024
10.98
Maximum
Sep 04 2019
7.252
Average
7.177
Median
Price to Book Value Benchmarks
| Ascendis Pharma A/S | -- |
| Novo Nordisk A/S | 34.96 |
| Galecto Inc | 0.5975 |
| Evaxion Biotech AS | -- |
| IO Biotech Inc | 0.7570 |
Price to Book Value Related Metrics
| PE Ratio | 28.81 |
| PS Ratio | 7.637 |
| Price to Free Cash Flow | 17.97 |
| Price | 27.72 |
| Earnings Yield | 3.47% |
| Market Cap | 18.09B |
| Operating PE Ratio | 23.63 |
| Normalized PE Ratio | 26.63 |